CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Th17 responses are critical to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise. Here, we report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding pro...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
National Academy of Sciences
2015
|
| _version_ | 1826263762768756736 |
|---|---|
| author | Hammitzsch, A Tallant, C Fedorov, O O'Mahony, A Brennan, P Hay, D Martinez, F Al-Mossawi, M de Wit, J Vecellio, M Wells, C Wordsworth, B Müller, S Knapp, S Bowness, P |
| author_facet | Hammitzsch, A Tallant, C Fedorov, O O'Mahony, A Brennan, P Hay, D Martinez, F Al-Mossawi, M de Wit, J Vecellio, M Wells, C Wordsworth, B Müller, S Knapp, S Bowness, P |
| author_sort | Hammitzsch, A |
| collection | OXFORD |
| description | Th17 responses are critical to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise. Here, we report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding protein) and p300 as an alternative approach to inhibit human Th17 responses. We show that CBP30 has marked molecular specificity for the bromodomains of CBP and p300, compared with 43 other bromodomains. In unbiased cellular testing on a diverse panel of cultured primary human cells, CBP30 reduced immune cell production of IL-17A and other proinflammatory cytokines. CBP30 also inhibited IL-17A secretion by Th17 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis. Transcriptional profiling of human T cells after CBP30 treatment showed a much more restricted effect on gene expression than that observed with the pan-BET (bromo and extraterminal domain protein family) bromodomain inhibitor JQ1. This selective targeting of the CBP/p300 bromodomain by CBP30 will potentially lead to fewer side effects than with the broadly acting epigenetic inhibitors currently in clinical trials. |
| first_indexed | 2024-03-06T19:56:58Z |
| format | Journal article |
| id | oxford-uuid:25f1573a-8dd0-4ee6-9745-e9800bf28cee |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:56:58Z |
| publishDate | 2015 |
| publisher | National Academy of Sciences |
| record_format | dspace |
| spelling | oxford-uuid:25f1573a-8dd0-4ee6-9745-e9800bf28cee2022-03-26T11:58:26ZCBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:25f1573a-8dd0-4ee6-9745-e9800bf28ceeEnglishSymplectic Elements at OxfordNational Academy of Sciences2015Hammitzsch, ATallant, CFedorov, OO'Mahony, ABrennan, PHay, DMartinez, FAl-Mossawi, Mde Wit, JVecellio, MWells, CWordsworth, BMüller, SKnapp, SBowness, PTh17 responses are critical to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise. Here, we report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding protein) and p300 as an alternative approach to inhibit human Th17 responses. We show that CBP30 has marked molecular specificity for the bromodomains of CBP and p300, compared with 43 other bromodomains. In unbiased cellular testing on a diverse panel of cultured primary human cells, CBP30 reduced immune cell production of IL-17A and other proinflammatory cytokines. CBP30 also inhibited IL-17A secretion by Th17 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis. Transcriptional profiling of human T cells after CBP30 treatment showed a much more restricted effect on gene expression than that observed with the pan-BET (bromo and extraterminal domain protein family) bromodomain inhibitor JQ1. This selective targeting of the CBP/p300 bromodomain by CBP30 will potentially lead to fewer side effects than with the broadly acting epigenetic inhibitors currently in clinical trials. |
| spellingShingle | Hammitzsch, A Tallant, C Fedorov, O O'Mahony, A Brennan, P Hay, D Martinez, F Al-Mossawi, M de Wit, J Vecellio, M Wells, C Wordsworth, B Müller, S Knapp, S Bowness, P CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. |
| title | CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. |
| title_full | CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. |
| title_fullStr | CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. |
| title_full_unstemmed | CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. |
| title_short | CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. |
| title_sort | cbp30 a selective cbp p300 bromodomain inhibitor suppresses human th17 responses |
| work_keys_str_mv | AT hammitzscha cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT tallantc cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT fedorovo cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT omahonya cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT brennanp cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT hayd cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT martinezf cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT almossawim cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT dewitj cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT vecelliom cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT wellsc cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT wordsworthb cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT mullers cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT knapps cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses AT bownessp cbp30aselectivecbpp300bromodomaininhibitorsuppresseshumanth17responses |